Prediction of Reactivation After Antivascular Endothelial Growth Factor Monotherapy for Retinopathy of Prematurity: Multimodal Machine Learning Model Study

预测早产儿视网膜病变抗血管内皮生长因子单药治疗后的复发:多模态机器学习模型研究

阅读:3

Abstract

BACKGROUND: Retinopathy of prematurity (ROP) is the leading preventable cause of childhood blindness. A timely intravitreal injection of antivascular endothelial growth factor (anti-VEGF) is required to prevent retinal detachment with consequent vision impairment and loss. However, anti-VEGF has been reported to be associated with ROP reactivation. Therefore, an accurate prediction of reactivation after treatment is urgently needed. OBJECTIVE: To develop and validate prediction models for reactivation after anti-VEGF intravitreal injection in infants with ROP using multimodal machine learning algorithms. METHODS: Infants with ROP undergoing anti-VEGF treatment were recruited from 3 hospitals, and conventional machine learning, deep learning, and fusion models were constructed. The areas under the curve (AUCs), accuracy, sensitivity, and specificity were used to show the performances of the prediction models. RESULTS: A total of 239 cases with anti-VEGF treatment were recruited, including 90 (37.66%) with reactivation and 149 (62.34%) nonreactivation cases. The AUCs for the conventional machine learning model were 0.806 and 0.805 in the internal validation and test groups, respectively. The average AUC, sensitivity, and specificity in the test for the deep learning model were 0.787, 0.800, and 0.570, respectively. The specificity, AUC, and sensitivity for the fusion model were 0.686, 0.822, and 0.800 in a test, separately. CONCLUSIONS: We constructed 3 prediction models for ROP reactivation. The fusion model achieved the best performance. Using this prediction model, we could optimize strategies for treating ROP in infants and develop better screening plans after treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。